Friday, 15 Feb 2019

You are here

Maastricht Study Links Dairy Intake to Osteoarthritis

The Maastricht study explored the potential association between dairy consumption and knee osteoarthritis (OA), and found that higher intake of full-fat dairy and Dutch cheese - but not milk - was significantly associated with the lower risk of knee OA.

They studied in 3010 individuals aged 40–75 years and compared non-OA to 427 (14%) participants who were classified as having knee OA based on a modified version of the American College of Rheumatology clinical classification criteria (minus knee crepitus measure) for knee OA.  Data on dairy consumption were appraised using a 253-item survey covering 47 dairy products.

By comparing the highest and lowest tertiles of dairy intake, they found significant inverse association between knee OA and intake of full-fat dairy.

  • OR = 0.68 (95%CI 0.50–0.92) for full-fat dairy
  • OR = 0.75 (95%CI 0.56–0.99) for Dutch cheese (i.e., Gouda, Edam or Maasdam)
  • No significant associations were found for other dairy product categories, including milk

Further research is called for to assess the relationship between dairy consumption, and in particular semi-hard cheeses, with incident knee OA.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Opioid Use in Osteoarthritis Varies by State

A study in Arthritis & Rheumatology shows that there is substantial statewide variation in rates of treatment with long‐term opioid therapy in osteoarthritis - not fully explained by differences in access to healthcare providers, varying case‐mix, or state‐level policies.

Vertebroplasty and Kyphoplasty Shown to Be Ineffective

There are approximately 750,000 new vertebral compression fractures each year in the United States, with resultant acute and chronic back pain in over one‐third of patients with vertebral fractures (VF).  Both percutaneous vertebroplasty or balloon kyphoplasty have been advocated as useful means of restoring vertebral height and strength capable of reducing pain in symptomatic patients.

FDA Panel Backs Approval of Romosuzumab for Osteoporosis

The US Food and Drug Administration’s advisory committee on Bone, Reproductive and Urologic Drugs voted Wednesday in favor of approving Amgen’s osteoporosis anti-sclerostin drug, romosozumab (Evenity) for use women with postmenopausal osteoporosis. 

Reuters reports that the panel voted 16-1 in favor of the monthly injection developed jointly by UCB.

Heberden’s Nodes Predict Knee OA Progression

Hand and knee osteoarthritis are considered to be clinically and pathogenically different and distinct, but a new study suggests that Heberden's nodes (HNs) can predict MRI‐based knee osteoarthritis (OA) progression.

An NIH study of 575 subjects included clinical examination with evaluation of HNs at baseline and knee MRI at baseline and 24‐month.

NEJM Review - Glucocorticoid-Induced Osteoporosis

Lenore Buckley and Mary Humphrey have published a nice review of glucocorticoid-induced osteoporosis (GIOP) in the NEJM.